Compared side by side

Mazdutide vs survodutide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both are weekly GLP-1 and glucagon dual agonists: mazdutide is built on oxyntomodulin, a gut hormone that acts on both receptors, and survodutide on the glucagon sequence, fully activating the GLP-1 receptor and partly the glucagon receptor. Mazdutide was approved in China in 2025 and isn’t FDA-approved; survodutide isn’t approved, and its phase 3 results were published in 2026. In phase 3, people lost about 11% (4 mg) and 14% (6 mg) of their weight at 48 weeks on mazdutide, and 12–13% at 76 weeks counting everyone on survodutide.

Side by side

ComparedMazdutideSurvodutide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asIBI362, LY3305677, XinermeiBI 456906, BI456906, Survo
What it isA once-weekly GLP-1 and glucagon dual agonist from Innovent and Eli Lilly, approved in China in 2025 for weight management (as Xinermei) and type 2 diabetes; it is not FDA-approved.A weekly shot that activates two receptors: GLP-1, for appetite and blood sugar, and glucagon, which clears fat from the liver and, in mice, raises energy use.
How it worksOnce-weekly GLP-1 and glucagon receptor dual agonist built on oxyntomodulin, a gut hormone that acts on both receptors, with a C20 fatty-acid side chain that stretches its half-life to about 10 days. The GLP-1 arm curbs appetite; the glucagon arm adds energy expenditure (shown in mice). Developed by Innovent with Eli Lilly and approved in China in 2025 for weight management and type 2 diabetes. Its label steps the dose up every 4 weeks from 2 mg, and GI side effects come mostly during those step-ups.Glucagon and GLP-1 receptor dual agonist: a 29-amino-acid peptide built on the glucagon sequence, carrying a C18 fatty acid that binds albumin for once-weekly dosing. It fully activates the GLP-1 receptor (appetite, insulin) and partly activates the glucagon receptor, which raises energy expenditure (shown in mice) and draws down liver fat (the liver-fat drop is measured in people). Developed by Boehringer Ingelheim with Zealand Pharma; its phase 3 (SYNCHRONIZE) results were published in 2026, and it is not approved.
Commonly reportedStrong appetite suppression and GI side effects after each step-up, much as with other weekly GLP-1s; user reports from outside China are still few.Less appetite and early fullness, with nausea or vomiting during the long dose climb and a resting heart rate a few beats higher. Average weight loss at 76 weeks was 12–13% counting everyone and up to 16.6% for people who stayed on it, and most people in its liver trial cut their liver fat by at least 30%.
Studied rangeResearch range: 2–6 mg, starting dose 2 mg. Studied in research — not a recommendation.Research range: 0.3–6 mg, starting dose 0.3 mg. Studied in research — not a recommendation.
How oftenWeeklyWeekly
Half-life~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes)Long enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries
RouteSubQ injectionSubQ injection
Typical runUsed continuously, once weekly, in its trials and label. Per the label, a dose 1 to 3 weeks late (2 to 4 weeks since the last one) restarts one dose step lower, and more than 3 weeks late restarts the 2 mg step. No trial has tested stopping it.Phase 3 trials run it continuously for 76 weeks after a slow climb of about 24 weeks. Not approved; Boehringer Ingelheim expects its cardiovascular outcomes trial to report later in 2026.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid refluxNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, higher resting heart rate

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking mazdutide or survodutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Mazdutide

  • Day 1–28 · 2 mg Appetite first, scale later
  • Day 29–56 · 4 mg A maintenance dose, not just a step
  • Day 57–224 · 4 mg Holding at 4 mg
  • Day 57–224 · 6 mg The top labelled dose
  • Day 225–336 Weeks 32 to 48: still moving, more slowly
  • Day 337+ A maintenance medication, not a course

Every card for mazdutide, with its sources

Survodutide

  • Day 1–14 · 0.3 mg The 0.3 mg start
  • Day 15–168 The slow climb
  • Day 99+ · 3.6 mg 3.6 mg, the lower phase 3 dose
  • Day 141+ · 6 mg 6.0 mg, the top phase 3 dose
  • Day 169–336 Liver fat: where the glucagon arm shows

Every card for survodutide, with its sources

Questions people ask

How long do mazdutide and survodutide last?

The half-life of mazdutide is ~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes). The half-life of survodutide is long enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries.

How often are mazdutide and survodutide taken?

Mazdutide: weekly. Route: SubQ injection. Survodutide: weekly. Route: SubQ injection.

How are mazdutide and survodutide dosed in research?

The research range for mazdutide is 2–6 mg, with a 2 mg starting dose. The research range for survodutide is 0.3–6 mg, with a 0.3 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of mazdutide and survodutide?

For mazdutide, the library lists: nausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid reflux. For survodutide: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, higher resting heart rate.

Each one in full

Track it in the app

PepVault for iPhone

Taking mazdutide or survodutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo